STOCK TITAN

Bio-Techne Corrects Dividend Announcement

(Neutral)
Tags
dividends

Bio-Techne (NASDAQ: TECH) issued a correction to its recent dividend announcement, changing the shareholder of record date from August 17, 2026, to August 24, 2026. The Board approved a quarterly cash dividend of $0.08 per share, payable on August 28, 2026 to common shareholders of record on August 24, 2026; all other dividend details remain unchanged.

Loading...
Loading translation...

Positive

  • Quarterly dividend declared at $0.08 per share, payable August 28, 2026

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026. The correct shareholder of record date is August 24, 2026. All other information contained in the dividend announcement remains unchanged.

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 24, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio‑Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer‑focused brands: R&D Systems™, Bio‑Techne Spatial™, and Bio‑Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision‑making. Bio‑Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedInX, or YouTube

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact:

David Clair, Vice President, Investor Relations


David.Clair@bio-techne.com


612-656-4416

Bio-Techne

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-corrects-dividend-announcement-302850255.html

SOURCE Bio-Techne Corporation

FAQ

What dividend did Bio-Techne (NASDAQ: TECH) declare for the quarter ended June 30, 2026?

Bio-Techne declared a quarterly cash dividend of $0.08 per share for the quarter ended June 30, 2026. According to Bio-Techne, this dividend will be paid to all common shareholders of record on August 24, 2026, with payment on August 28, 2026.

What is the correct shareholder of record date for Bio-Techne (TECH) dividend in August 2026?

The correct shareholder of record date for Bio-Techne’s dividend is August 24, 2026. According to Bio-Techne, this corrects a previous announcement that mistakenly listed August 17, 2026, while all other dividend terms remain unchanged.

When will Bio-Techne (TECH) pay its $0.08 dividend for the June 30, 2026 quarter?

Bio-Techne will pay the $0.08 per share quarterly dividend on August 28, 2026. According to Bio-Techne, shareholders must be on record as common shareholders by August 24, 2026, to be eligible for this cash dividend payment.

Did Bio-Techne change the amount of the TECH dividend in its August 13, 2026 correction?

Bio-Techne did not change the dividend amount; it remains $0.08 per share. According to Bio-Techne, only the shareholder of record date was corrected to August 24, 2026, with all other dividend information staying the same.

How often does Bio-Techne (TECH) consider future cash dividends for shareholders?

Future cash dividends are considered by Bio-Techne’s Board of Directors on a quarterly basis. According to Bio-Techne, the Board evaluates and decides on dividends each quarter, so future payments are not guaranteed and depend on Board decisions.

How large is Bio-Techne’s business supporting its TECH dividend policy?

Bio-Techne reported over $1.2 billion in net sales in fiscal year 2026. According to Bio-Techne, the company operates in 34 locations worldwide, employs about 3,000 people, and offers more than 500,000 products for research and diagnostics customers.